A Secret Weapon For "3
All enrolled sufferers who received at the very least 1 dose of zosuquidar or placebo during induction ended up monitored for your event of adverse gatherings (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse activities have been related to the period of extended and substantial myelosuppression as is anticipated with in